MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.apsb.2024.05.026

Медицинская библиотека · Acta pharmaceutica Sinica. B · 2024

Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics.

Chan Chris Chun-Yiu, Guo Qian, Chan Jasper Fuk-Woo, Tang Kaiming, Cai Jian-Piao, Chik Kenn Ka-Heng, Huang Yixin, Dai Mei, Qin Bo, Ong Chon Phin, Chu Allen Wing-Ho, Chan Wan-Mui, Ip Jonathan Daniel, Wen Lei, Tsang Jessica Oi-Ling, Wang Tong-Yun, Xie Yubin, Qin Zhenzhi, Cao Jianli, Ye Zi-Wei, Chu Hin, To Kelvin Kai-Wang, Ge Xing-Yi, Ni Tao, Jin Dong-Yan, Cui Sheng, Yuen Kwok-Yung, Yuan Shuofeng

СтатьяПеревод в очереди

Аннотация

There are only eight approved small molecule antiviral drugs for treating COVID-19. Among them, four are nucleotide analogues (remdesivir, JT001, molnupiravir, and azvudine), while the other four are protease inhibitors (nirmatrelvir, ensitrelvir, leritrelvir, and simnotrelvir-ritonavir). Antiviral resistance, unfavourable drug‒drug interaction, and toxicity have been reported in previous studies. Thus there is a dearth of new treatment options for SARS-CoV-2. In this work, a three-tier cell-based screening was employed to identify novel compounds with anti-SARS-CoV-2 activity. One compound, designated 172, demonstrated broad-spectrum antiviral activity against multiple human pathogenic coronaviruses and different SARS-CoV-2 variants of concern. Mechanistic studies validated by reverse genetics showed that compound 172 inhibits the 3-chymotrypsin-like protease (3CLpro) by binding to an allosteric site and reduces 3CLpro dimerization. A drug synergistic checkerboard assay demonstrated that compound 172 can achieve drug synergy with nirmatrelvir in vitro. In vivo studies confirmed the antiviral activity of compound 172 in both Golden Syrian Hamsters and K18 humanized ACE2 mice. Overall, this study identified an alternative druggable site on the SARS-CoV-2 3CLpro, proposed a potential combination therapy with nirmatrelvir to reduce the risk of antiviral resistance and shed light on the development of allosteric protease inhibitors for treating a range of coronavirus diseases.

Для цитирования: Chan Chris Chun-Yiu, Guo Qian, Chan Jasper Fuk-Woo, Tang Kaiming, Cai Jian-Piao, Chik Kenn Ka-Heng, Huang Yixin, Dai Mei, Qin Bo, Ong Chon Phin, Chu Allen Wing-Ho, Chan Wan-Mui, Ip Jonathan Daniel, Wen Lei, Tsang Jessica Oi-Ling, Wang Tong-Yun, Xie Yubin, Qin Zhenzhi, Cao Jianli, Ye Zi-Wei, Chu Hin, To Kelvin Kai-Wang, Ge Xing-Yi, Ni Tao, Jin Dong-Yan, Cui Sheng, Yuen Kwok-Yung, Yuan Shuofeng. Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics.. Acta pharmaceutica Sinica. B. 2024. DOI: 10.1016/j.apsb.2024.05.026.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.